Genitourinary Cancer – Page 2 – Medical News Asia

Erdafitinib FDA approved for the treatment of metastatic urothelial carcinoma

22 April 2019/0 Comments/in Genitourinary Cancer, US FDA Onc\Haem Approvals, Oncology, Targeted Therapies/by scienterrific

On 12 April 2019, the FDA granted accelerated approval to erdafitinib (Balversa®, Janssen) for the treatment of locally advanced or metastatic urothelial cell carcinoma (mUCC) progressed during or following a platinum-containing regimen, including progression within 12 months of (neo)adjuvant platinum-based chemotherapy, and whose tumours harbour susceptible fibroblast growth factor receptor (FGFR) 3 or FGFR2 genetic alterations as determined by the FDA approved companion diagnostic (CDx), the therascreen® FGFR RGQ RT-PCR Kit by Qiagen.

Combinations: upcoming treatment strategies in metastatic renal cell carcinoma

5 March 2019/Enter your password to view comments./in Genitourinary Cancer, Uncategorised, Oncology, Immunotherapy, Translational Research/by Stijn van den Borne, MSc

There is no excerpt because this is a protected post.

Management of Immune-Mediated Hepatitis: a Case Report

31 October 2018/Enter your password to view comments./in China, Genitourinary Cancer, Oncology, Immunotherapy, irAE Management/by Stijn van den Borne, MSc

There is no excerpt because this is a protected post.

First-in-Class Oncology Vaccine BIL06v Starts Phase 1 Evaluation

22 August 2018/0 Comments/in Breast Cancer, Medical News Asia, Genitourinary Cancer, Lung Cancer, Oncology, Melanoma & Skin Cancer, Immunotherapy, Translational Research/by scienterrific

Biosceptre has announced the initiation of its Phase 1 clinical study with the peptide vaccine BIL06v. BIL06v is a peptide-protein conjugate that recruits the patient’s immune system to make antibodies specifically targeted at nfP2X7-expressing cancer cells resulting in tumour cell death.

Pembrolizumab and atezolizumab USPIs updated by FDA

21 August 2018/1 Comment/in US FDA Onc\Haem Approvals, Genitourinary Cancer, Oncology, Immunotherapy/by scienterrific

On the 16th of August, 2018, the FDA updated the prescribing information for pembrolizumab (Keytruda®, Merck) and atezolizumab (Tecentriq®, Roche/Genentech) and added the requirement for the use of an FDA-approved companion diagnostic test (CDx) to determine PD-L1 levels in cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Enzalutamide FDA approved for castration-resistant prostate cancer (CRPC)

17 July 2018/0 Comments/in Genitourinary Cancer, US FDA Onc\Haem Approvals, Oncology, Endocrine Therapy/by scienterrific

On July 13, the FDA approved enzalutamide (Xtandi©, Astellas), for use in patients with castration-resistant prostate cancer (CRPC).

FDA limits use of atezolizumab and pembrolizumab in urothelial carcinoma

19 June 2018/1 Comment/in US FDA Onc\Haem Approvals, Genitourinary Cancer, Oncology, Immunotherapy, Translational Research/by scienterrific

On June 19, the FDA limited the use of atezolizumab and pembrolizumab for the treatment of locally advanced or metastatic urothelial cancer patients ineligible for cisplatin-containing therapy.

Frontline nivolumab plus ipilimumab approved for intermediate or poor risk advanced RCC

16 April 2018/0 Comments/in Genitourinary Cancer, US FDA Onc\Haem Approvals, Oncology, Immunotherapy/by scienterrific

The FDA granted approvals to nivolumab and ipilimumab (Opdivo and Yervoy, Bristol-Myers Squibb) in combination for the treatment of intermediate or poor risk, previously untreated advanced renal cell carcinoma.

Everolimus suspension approved in TSC-associated partial-onset seizures

10 April 2018/0 Comments/in Genitourinary Cancer, US FDA Onc\Haem Approvals, Oncology/by scienterrific

On April 10, the FDA approved everolimus tablets for oral suspension (Afinitor Disperz®, Novartis) for the adjunctive treatment of adult and pediatric patients ≥2 years with tuberous sclerosis complex (TSC)-associated partial-onset seizures.

Achieving Long-Term Survival in the First-Line Treatment of Metastatic Renal Cell Carcinoma; A Balancing Act of Efficacy and Side-Effects

8 January 2018/Enter your password to view comments./in Genitourinary Cancer, Uncategorised, Oncology, AE Management, Targeted Therapies/by Stijn van den Borne, MSc

There is no excerpt because this is a protected post.